ACME Laboratories (DHA:ACMELAB) Total Equity: BDT27,989 Mil (As of Mar. 2026)


DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
90 GF Score
Price BDT82.60
GF Value BDT125.24
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Total Equity?

ACME Laboratories DHA:ACMELAB 90 Total Equity is BDT27,989 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 90/100 and a GF Value™ of BDT125.24 (Possible Value Trap). The stock has 7 warning signs investors should review.

ACME Laboratories's total equity for the quarter that ended in Mar. 2026 was BDT27,989 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ACME Laboratories Total Equity Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Total Equity Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Equity
Get a 7-Day Free Trial Premium Member Only 19,044.18 20,110.60 21,690.12 23,295.12 25,051.83

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25,470.68 26,065.76 27,377.23 27,290.16 27,989.27
DHA:ACMELAB
90GF Score
ACME Laboratories Ltd DHA:ACMELAB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ACME Laboratories's Total Equity for the fiscal year that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=55622.164-30570.334
=25,052

ACME Laboratories's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=59535.015-31545.748
=27,989

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of BDT27,989 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Total Equity of BDT27,989 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ACME Laboratories and its competitors.
Is ACME Laboratories' Total Equity too high?
ACME Laboratories' current Total Equity is BDT27,989 Mil. Overall, ACME Laboratories has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Total Equity compare to ZTS and UTHR?
ACME Laboratories' Total Equity of BDT27,989 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ACME Laboratories and its competitors. ACME Laboratories's current Total Equity is BDT27,989 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.24, compared to a current price of BDT82.60 — trading 34% below its estimated fair value. The current Total Equity is BDT27,989 Mil. ACME Laboratories' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Total Equity is BDT27,989 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT82.60 is trading 34% below its estimated GF Value™ of BDT125.24. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Total Equity: BDT27,989 Mil
  • GF Value™: BDT125.24 vs. price of BDT82.60 (34% below fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
90GF Score

Get the complete analysis for DHA:ACMELAB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT82.60
Price
BDT125.24
GF Value